Single Dose Gonadotropin-releasing Hormone (GnRH) Agonist Administration in the Luteal Phase of GnRH Antagonist Stimulated ICSI-ET Cycles
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 试验地点
- 1
- 主要终点
- Ongoing pregnancy beyond 20th gestational week
研究概览
简要总结
GnRH agonist administration in the luteal phase was reported to beneficially affect clinical outcome of ICSI-ET cycles. This randomized controlled trial evaluates the effect of a single dose GnRH agonist administered in the luteal phase on the outcome of ICSI - ET cycles stimulated with the fixed GnRH antagonist protocol. Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol were included. In addition to routine luteal phase support with progesterone women were randomized to receive a single dose of GnRH agonist or placebo on the sixth day after ICSI.Ongoing pregnancy rate was the primary outcome measure.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women undergoing embryo transfer following controlled ovarian hyperstimulation with a fixed GnRH antagonist protocol, oocyte pick-up and ICSI.
- •Embryo transfer performed on day 3
排除标准
- •Participation in another trial that was being conducted in our unit at the same time.
- •Preimplantation genetic screening cycles.
- •Day 5 embryo transfers.
研究组 & 干预措施
Saline
干预措施: NaCl %0.9 (Drug)
GnRH agonist
干预措施: triptorelin acetate (Drug)
结局指标
主要结局
Ongoing pregnancy beyond 20th gestational week
次要结局
- clinical pregnancy rate
- Embryo implantation rate